BRPI0412110A - genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos - Google Patents

genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos

Info

Publication number
BRPI0412110A
BRPI0412110A BRPI0412110-4A BRPI0412110A BRPI0412110A BR PI0412110 A BRPI0412110 A BR PI0412110A BR PI0412110 A BRPI0412110 A BR PI0412110A BR PI0412110 A BRPI0412110 A BR PI0412110A
Authority
BR
Brazil
Prior art keywords
ovarian cancer
prognostic
therapeutic targets
genes regulated
relates
Prior art date
Application number
BRPI0412110-4A
Other languages
English (en)
Inventor
Christian Nicolas Lavedan
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0412110A publication Critical patent/BRPI0412110A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"GENES REGULADOS NO CáNCER OVARIANO COMO ALVOS PROGNóSTICOS E TERAPêUTICOS". A presente invenção refere-se à aplicação de análise genómica para detectar a presença de câncer ovariano em uma paciente a partir de uma amostra de tecido ou sangue e a kits para realizar esta determinação. Além disso, esta invenção refere-se a métodos para tratar uma paciente com câncer ovariano.
BRPI0412110-4A 2003-07-02 2004-07-01 genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos BRPI0412110A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48446503P 2003-07-02 2003-07-02
PCT/EP2004/007167 WO2005005661A2 (en) 2003-07-02 2004-07-01 Genes regulated in ovarian cancer as prognostic and therapeutic targets

Publications (1)

Publication Number Publication Date
BRPI0412110A true BRPI0412110A (pt) 2006-11-21

Family

ID=34062046

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412110-4A BRPI0412110A (pt) 2003-07-02 2004-07-01 genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos

Country Status (8)

Country Link
EP (1) EP1644522A2 (pt)
JP (1) JP2007526749A (pt)
CN (1) CN1845999A (pt)
AU (1) AU2004256182A1 (pt)
BR (1) BRPI0412110A (pt)
CA (1) CA2531091A1 (pt)
MX (1) MXPA05014220A (pt)
WO (1) WO2005005661A2 (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100068207A1 (en) * 2005-04-07 2010-03-18 Abdallah Fanidi DDR2 in Cancer Diagnosis, Detection and Treatment
EP1806413A1 (en) * 2006-01-06 2007-07-11 Oligene GmbH An in-vitro-method and means for determination of different tumor types and predicting success of surgical procedures in ovarian cancer
AU2007321070B2 (en) * 2006-11-13 2013-11-21 Valipharma Methods and uses involving genetic abnormalities at chromosome 12
GB0815846D0 (en) * 2008-09-01 2008-10-08 Immunovia Ab diagnosis, prognosis and imaging of disease
NZ617003A (en) 2010-01-11 2015-04-24 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
WO2012025616A1 (en) * 2010-08-27 2012-03-01 Universitaetsklinikum Muenster Means and methods for the detection of a predisposition of a female subject to recurrent pregnancy loss (rpl), preeclampsia (pe) and/or fetal growth restriction (fgr)
JP2016521979A (ja) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
CN103920150B (zh) * 2014-04-17 2016-02-03 北京大学第一医院 Satb1在治疗皮肤t细胞淋巴瘤中的应用
JP6436477B2 (ja) * 2014-05-13 2018-12-12 国立大学法人大阪大学 癌治療用医薬組成物
JP6168625B2 (ja) * 2016-01-12 2017-07-26 国立研究開発法人産業技術総合研究所 上皮性卵巣癌鑑別マーカー
CN106841622B (zh) * 2017-04-07 2019-01-18 南通大学附属医院 Scml2在诊断胃肠胰神经内分泌肿瘤中的应用
CN108085392A (zh) * 2018-01-09 2018-05-29 山大生殖研发中心有限公司 上皮性卵巢癌的生物标志物及其用途
CN110241198A (zh) * 2019-05-30 2019-09-17 成都吉诺迈尔生物科技有限公司 一种表征hHRD同源重组缺陷的基因组重组指纹及其鉴定方法
CN112229999B (zh) * 2020-09-01 2022-04-22 浙江省肿瘤医院 一种卵巢癌的预后诊断标志物Claudin21及其应用
CN113684277B (zh) * 2021-09-06 2022-05-17 南方医科大学南方医院 一种基于基因组拷贝数变异的生物标志物预测卵巢癌同源重组缺陷的方法及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7701100A (en) * 1999-09-03 2001-04-10 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US20030165831A1 (en) * 2000-03-21 2003-09-04 John Lee Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US20030003479A1 (en) * 2001-04-19 2003-01-02 Millennium Pharmaceutical, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
AU2002324881A1 (en) * 2001-09-05 2003-03-18 Wesleyan University Diagnostic and prognostic tests

Also Published As

Publication number Publication date
MXPA05014220A (es) 2006-03-09
CN1845999A (zh) 2006-10-11
WO2005005661A3 (en) 2005-07-14
AU2004256182A1 (en) 2005-01-20
WO2005005661A2 (en) 2005-01-20
JP2007526749A (ja) 2007-09-20
CA2531091A1 (en) 2005-01-20
EP1644522A2 (en) 2006-04-12

Similar Documents

Publication Publication Date Title
BRPI0412110A (pt) genes regulados no cáncer ovariano como alvos prognósticos e terapêuticos
BRPI0518086A (pt) métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2005117553A3 (en) Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
AU2003253986A1 (en) Gene expression profiling in biopsied tumor tissues
WO2008018642A3 (en) Genes and polypeptides relating to breast cancers
PT991421E (pt) Deteccao e modulacao das iap e naip para o diagnostico e tratamento de doenca proliferativa
ATE445160T1 (de) Diagnostische marker für schlaganfall und hirntrauma sowie verfahren zur verwendung davon
DK3059322T3 (da) Genekspressionsmarkører for brystcancerprognose
DE602006015966D1 (de) Verfahren zur vorhersage und überwachung einer unmittelbaren reaktion auf eine krebstherapie
WO2004106495A3 (en) Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2005113831A3 (en) Biomarkers for multiple sclerosis and methods of use thereof
DK2114990T3 (da) Fremgangsmåde til forudsigelse af NSCLC-patienters respons på behandling med en EGFR-TK-inhibitor
WO2012116229A3 (en) Compositions and methods for personal tumor profiling treatment
DE602006012995D1 (de) Brustkrebsdiagnoseverfahren
WO2009019370A3 (fr) Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal
BRPI0503418A (pt) prognóstico para malignidade hematológica
BR112012005670A2 (pt) ''método para a identificação de um paciente com câncer que pode se beneficiar com a terapia antiagiogênica, método para a predição da responsividade de um paciente com câncer à terapia antiangiogênica, uso de um anticorpo anto- vegf para melhorar o efeito do tratamento de um paciente sofrendo de câncer, método ou uso, kit útil para realizar o método, uso de uma proteína ou usom kit útil para realizar o método, uso de uma proteína ou oligonucleotídeo ou matriz de polinecleotídeo para determinar o nível de expressão de bfgf em um método e kit ou uso
AU2003293141A1 (en) Methods for identifying risk of breast cancer and treatments thereof
ATE432997T1 (de) Therapieüberwachung für tumoren unter benutzung acc133 mrna
BRPI0515794A (pt) processos para avaliar pacientes com leucemia mielóide aguda
WO2007020522A3 (en) Protein markers for diagnosing of colorectal cancer and use of said markers as drug targets for the treatment of said cancer type
WO2009003706A3 (en) Methods, kits, and compounds for determining responsiveness to treatment of a pathological disorder by epothilones
CY1105566T1 (el) Ποσοτικη διαγνωστικη αναλυση της προδιαθεσης για υπερταση

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired